News

Each 1000mg injection of Nebido would only need to be provided once every 12 weeks, as compared to the current injectable therapies which typically require an injection every

DRC will also provide a $15 million milestone payment in 2012 should certain royalty recognition levels be met. Peg-Intron (peginterferon alpha-2b), is approved for the treatment of hepatitis

In the collaboration, Californian drug developer KineMed will identify new therapeutic utility in in vivo preclinical models by applying its proprietary translational medicine technologies. Once a disease target

The product, prGCD, is a proprietary plant cell expressed recombinant form of human Glucocerebrosidase (GCD). The Phase III clinical trial will take place in centers in the US,

Tezampanel will be given as a subcutaneous injection to healthy male and female volunteers once-daily for four consecutive days. The compound is an AMPA/kainate (AK) receptor antagonist that

Pfizer's DGAT-1 discovery program includes advanced preclinical compounds with potential applications for the treatment of metabolic disorders, as well as DGAT-1 inhibitors in-licensed by Pfizer from Bayer in

The FDA has requested data from additional clinical trials to demonstrate the benefit of the drug. In anticipation of a not approvable letter from the FDA, the company

Carl Pelzel has been appointed president and CEO and to the company's board of directors. Mr Pelzel has been Depomed's executive vice president and COO since 2005. Craig

Under the agreement, Ipca will develop and register selected products for US ANDA submission, while Heritage will retain sales and marketing rights to such products. The parties shall